The DOI matches its Crossref record.
Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1
Open accessAbstract
OBJECTIVE: To determine if mexiletine is safe and effective in reducing myotonia in myotonic dystrophy type 1 (DM1). BACKGROUND: Myotonia is an early, prominent symptom in DM1 and contributes to decreased dexterity, gait instability, difficulty with speech/swallowing, and muscle pain. A few preliminary trials have suggested that the antiarrhythmic drug mexiletine is useful, symptomatic treatment for nondystrophic myotonic disorders and DM1. METHODS: We performed 2 randomized, double-blind, placebo-controlled crossover trials, each involving 20 ambulatory DM1 participants with grip or percussion myotonia on examination. The initial trial compared 150 mg of mexiletine 3 times daily to placebo, and the second trial compared 200 mg of mexiletine 3 times daily to placebo. Treatment periods were 7 weeks in duration separated by a 4- to 8-week washout period. The primary measure of myotonia was time for isometric grip force to relax from 90% to 5% of peak force after a 3-second maximum grip contraction. EKG measurements and adverse events were monitored in both trials. RESULTS: There was a significant reduction in grip relaxation time with both 150 and 200 mg dosages of mexiletine. Treatment with mexiletine at either dosage was not associated with any serious adverse events, or with prolongation of the PR or QTc intervals or of QRS duration. Mild adverse events were observed with both placebo and mexiletine treatment. CONCLUSIONS: Mexiletine at dosages of 150 and 200 mg 3 times daily is effective, safe, and well-tolerated over 7 weeks as an antimyotonia treatment in DM1. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that mexiletine at dosages of 150 and 200 mg 3 times daily over 7 weeks is well-tolerated and effective in reducing handgrip relaxation time in DM1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Thornton, C. A. (2014) · Neurologic Clinics · doi:10.1016/j.ncl.2014.04.011 · Cited by 377
Self-citationMeola, G., & Cardani, R. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.019 · Cited by 347
Skeletal Muscle Degenerative Diseases and Strategies for Therapeutic Muscle Repair
Tabebordbar, M., Wang, E. T., & Wagers, A. J. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132450 · Cited by 79
Voxel-based diffusion tensor imaging of an APP/PS1 mouse model of Alzheimer’s disease.
Shu, X., Qin, Y.-Y., Zhang, S., Jiang, J.-J., Zhang, Y., Zhao, L.-Y., Shan, D., & Zhu, W.-Z. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8418-6 · Cited by 41
Metadata
- Authors
- Logigian, E. L., Martens, W. B., Moxley, R. T., McDermott, M. P., Dilek, N., Wiegner, A. W., Pearson, A. T., Barbieri, C. A., Annis, C. L., Thornton, C. A., & Moxley, R. T.
- Venue
- Neurology
- Published
- 2010-05-04
- Volume
- 74
- Issue
- 18
- Pages
- 1441-1448
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1983101498
- Cited by
- 203
- References
- 0
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. https://app.cochat.ai/papers/10.1212/wnl.0b013e3181dc1a3a
- The paper
- Logigian, E. L., Martens, W. B., Moxley, R. T., McDermott, M. P., Dilek, N., Wiegner, A. W., Pearson, A. T., Barbieri, C. A., Annis, C. L., Thornton, C. A., & Moxley, R. T. (2010). Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology. https://doi.org/10.1212/wnl.0b013e3181dc1a3a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.